NATCO Pharma Future Growth
Future criteria checks 0/6
NATCO Pharma's revenue and earnings are forecast to decline at 5.1% and 20.4% per annum respectively. EPS is expected to decline by 19.5% per annum. Return on equity is forecast to be 17.8% in 3 years.
Key information
-20.4%
Earnings growth rate
-19.5%
EPS growth rate
| Pharmaceuticals earnings growth | 17.8% |
| Revenue growth rate | -5.1% |
| Future return on equity | 17.8% |
| Analyst coverage | Good |
| Last updated | 20 Nov 2024 |
Recent future growth updates
Recent updates
NATCO Pharma (NSE:NATCOPHARM) Has Announced A Dividend Of ₹1.50
Nov 18
Earnings Beat: NATCO Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Nov 15We Ran A Stock Scan For Earnings Growth And NATCO Pharma (NSE:NATCOPHARM) Passed With Ease
Oct 13NATCO Pharma Limited's (NSE:NATCOPHARM) Shares Bounce 26% But Its Business Still Trails The Market
Aug 13If EPS Growth Is Important To You, NATCO Pharma (NSE:NATCOPHARM) Presents An Opportunity
Jul 15NATCO Pharma (NSE:NATCOPHARM) Seems To Use Debt Rather Sparingly
Jun 30NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings Are Not Doing Enough For Some Investors
Jun 14NATCO Pharma Limited (NSE:NATCOPHARM) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models
May 30Calculating The Fair Value Of NATCO Pharma Limited (NSE:NATCOPHARM)
May 09Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?
Apr 03NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25
Feb 21NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next
Feb 18NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement
Feb 17Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jan 25An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued
Jan 09Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?
Dec 13An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued
Sep 30Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today
Sep 12NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year
Aug 12Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jul 16NATCO Pharma Limited (NSE:NATCOPHARM) Shares Could Be 44% Below Their Intrinsic Value Estimate
Apr 20Is NATCO Pharma Limited (NSE:NATCOPHARM) Trading At A 46% Discount?
Dec 20NATCO Pharma's (NSE:NATCOPHARM) Upcoming Dividend Will Be Larger Than Last Year's
Aug 12Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?
Jun 23Broker Revenue Forecasts For NATCO Pharma Limited (NSE:NATCOPHARM) Are Surging Higher
Jun 02Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2027 | 37,151 | 8,965 | 12,188 | 15,176 | 8 |
| 3/31/2026 | 55,674 | 21,668 | 17,718 | 18,732 | 10 |
| 3/31/2025 | 50,546 | 21,570 | 15,571 | 16,763 | 9 |
| 9/30/2024 | 45,638 | 19,448 | 12,838 | 17,163 | N/A |
| 6/30/2024 | 43,490 | 16,365 | N/A | N/A | N/A |
| 3/31/2024 | 40,020 | 13,883 | 8,529 | 12,116 | N/A |
| 12/31/2023 | 38,298 | 12,778 | N/A | N/A | N/A |
| 9/30/2023 | 35,637 | 11,274 | 5,230 | 7,477 | N/A |
| 6/30/2023 | 29,630 | 8,152 | N/A | N/A | N/A |
| 3/31/2023 | 27,085 | 7,153 | 6,435 | 8,491 | N/A |
| 12/31/2022 | 24,074 | 3,890 | N/A | N/A | N/A |
| 9/30/2022 | 24,754 | 4,071 | 5,575 | 8,302 | N/A |
| 6/30/2022 | 24,191 | 4,154 | N/A | N/A | N/A |
| 3/31/2022 | 19,462 | 1,700 | -1,962 | 465 | N/A |
| 12/31/2021 | 16,833 | 2,735 | N/A | N/A | N/A |
| 9/30/2021 | 14,780 | 2,558 | -2,457 | 230 | N/A |
| 6/30/2021 | 18,990 | 3,931 | N/A | N/A | N/A |
| 3/31/2021 | 20,561 | 4,409 | 465 | 2,988 | N/A |
| 12/31/2020 | 21,756 | 4,820 | N/A | N/A | N/A |
| 9/30/2020 | 23,026 | 5,238 | 1,554 | 4,466 | N/A |
| 6/30/2020 | 19,861 | 4,404 | N/A | N/A | N/A |
| 3/31/2020 | 19,150 | 4,608 | 587 | 4,173 | N/A |
| 12/31/2019 | 19,159 | 4,875 | N/A | N/A | N/A |
| 9/30/2019 | 19,904 | 5,425 | -2,200 | 1,600 | N/A |
| 6/30/2019 | 20,482 | 6,060 | N/A | N/A | N/A |
| 3/31/2019 | 20,945 | 6,444 | 2,071 | 6,688 | N/A |
| 12/31/2018 | 24,066 | 8,235 | N/A | N/A | N/A |
| 9/30/2018 | 24,121 | 8,815 | N/A | N/A | N/A |
| 6/30/2018 | 22,953 | 7,838 | N/A | N/A | N/A |
| 3/31/2018 | 21,848 | 6,962 | N/A | 4,636 | N/A |
| 12/31/2017 | 19,817 | 5,730 | N/A | N/A | N/A |
| 9/30/2017 | 20,895 | 5,506 | N/A | 4,985 | N/A |
| 6/30/2017 | 21,679 | 5,323 | N/A | N/A | N/A |
| 3/31/2017 | 20,202 | 4,860 | N/A | 3,458 | N/A |
| 12/31/2016 | 17,697 | 3,680 | N/A | N/A | N/A |
| 9/30/2016 | 13,692 | 2,113 | N/A | N/A | N/A |
| 6/30/2016 | 12,431 | 1,748 | N/A | N/A | N/A |
| 3/31/2016 | 10,423 | 1,549 | N/A | 1,122 | N/A |
| 12/31/2015 | 9,355 | 1,494 | N/A | N/A | N/A |
| 9/30/2015 | 8,549 | 1,266 | N/A | N/A | N/A |
| 6/30/2015 | 8,390 | 1,294 | N/A | N/A | N/A |
| 3/31/2015 | 7,305 | 1,293 | N/A | 927 | N/A |
| 12/31/2014 | 8,089 | 1,042 | N/A | N/A | N/A |
| 9/30/2014 | 8,108 | 1,199 | N/A | N/A | N/A |
| 6/30/2014 | 7,648 | 1,144 | N/A | N/A | N/A |
| 3/31/2014 | 7,389 | 1,027 | N/A | 1,440 | N/A |
| 12/31/2013 | 7,078 | 900 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NATCOPHARM's earnings are forecast to decline over the next 3 years (-20.4% per year).
Earnings vs Market: NATCOPHARM's earnings are forecast to decline over the next 3 years (-20.4% per year).
High Growth Earnings: NATCOPHARM's earnings are forecast to decline over the next 3 years.
Revenue vs Market: NATCOPHARM's revenue is expected to decline over the next 3 years (-5.1% per year).
High Growth Revenue: NATCOPHARM's revenue is forecast to decline over the next 3 years (-5.1% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NATCOPHARM's Return on Equity is forecast to be low in 3 years time (17.8%).